BDBM221524 US9303045, 112::US9303045, 8::US9695195, 112

SMILES CN1C2COCC1CC(C2)NC(=O)c1cn(CC(F)(F)F)c2ccccc12

InChI Key

Data  3 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 221524   

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221524(US9303045, 112 | US9303045, 8 | US9695195, 112)
Affinity DataIC50: 0.530nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221524(US9303045, 112 | US9303045, 8 | US9695195, 112)
Affinity DataIC50: 0.530nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/6/2018
Entry Details
US Patent

Target5-hydroxytryptamine receptor 3A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221524(US9303045, 112 | US9303045, 8 | US9695195, 112)
Affinity DataIC50: 0.680nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
US Patent